Potential New Therapeutic Agents for Diabetic Kidney Disease

American Journal of Kidney Diseases

Volumn 55, Issue 5, 2010, Pages 928-940

  Turgut, Faruk ^a   Bolton, Warren Kline ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

advanced glycation; Diabetic nephropathy; therapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIFIBROTIC AGENT; APOCYNIN; AVOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; ENALAPRIL; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCOSAMINOGLYCAN; LOSARTAN; NEW DRUG; PENTOXIFYLLINE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRIDOXAMINE; RAMIPRIL; RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; SMP 534; SULODEXIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ALBUMINURIA; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG MECHANISM; FLUID RETENTION; GLOMERULUS BASEMENT MEMBRANE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN SECRETION; PROTEINURIA; RENAL PROTECTION; SIDE EFFECT; URINARY EXCRETION; VASOCONSTRICTION;

AMIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; CONNECTIVE TISSUE GROWTH FACTOR; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLYCOSAMINOGLYCANS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; HYDRAZINES; KIDNEY; NADPH OXIDASE; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; PYRIDOXAMINE; PYRIMIDINES; RECEPTORS, ENDOTHELIN; RECEPTORS, IMMUNOLOGIC; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN B COMPLEX;

EID: 77951622247     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.11.021     Document Type: Article

References (123)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 17 (2007) 2038-2047
2. Hebert L.A., Wilmer W.A., Falkenhain M.E., Ladson-Wofford S.E., Nahman Jr. N.S., and Rovin B.H. Renoprotection: one or many therapies?. Kidney Int 59 4 (2001) 1211-1226
3. Foley R.N., and Collins A.J. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 18 10 (2007) 2644-2648
4. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44 11 (2001) 1957-1972
5. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 12 (2001) 851-860
6. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 12 (2001) 861-869
7. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128 12 pt 1 (1998) 982-988
8. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 9069 (1997) 1857-1863
9. Tylicki L., Rutkowski P., Renke M., et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 52 3 (2008) 486-493
10. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 9638 (2008) 547-553
11. Suissa S., Hutchinson T., Brophy J.M., and Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69 5 (2006) 913-919
12. Thomas M.C., Baynes J.W., Thorpe S.R., and Cooper M.E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6 4 (2005) 453-474
13. Miyata T., van Ypersele de Strihou C., Kurokawa K., and Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55 2 (1999) 389-399
14. Forbes J.M., Thallas V., Thomas M.C., et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17 12 (2003) 1762-1764
15. Wendt T.M., Tanji N., Guo J., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162 4 (2003) 1123-1137
16. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., and Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91 24 (1994) 11704-11708
17. Brownlee M., Vlassara H., Kooney A., Ulrich P., and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 4758 (1986) 1629-1632
18. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., and Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40 10 (1991) 1328-1334
19. Friedman E.A., Distant D.A., Fleishhacker J.F., Boyd T.A., and Cartwright K. Aminoguanidine prolongs survival in azotemic-induced diabetic rats. Am J Kidney Dis 30 2 (1997) 253-259
20. Abdel-Rahman E., and Bolton W.K. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 11 4 (2002) 565-574
21. Bolton W.K., Cattran D.C., Williams M.E., et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24 1 (2004) 32-40
22. Williams M.E., Bolton W.K., Khalifah R.G., Degenhardt T.P., Schotzinger R.J., and McGill J.B. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27 6 (2007) 605-614
23. Guerrero-Romero F., Rodriguez-Moran M., Paniagua-Sierra J.R., Garcia-Bulnes G., Salas-Ramirez M., and Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43 2 (1995) 116-121
24. Rodriguez-Moran M., and Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients-a randomized, equivalent trial. Clin Nephrol 64 2 (2005) 91-97
25. Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Hu K., and Anderson P.W. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28 11 (2005) 2686-2690
26. Gambaro G., Kinalska I., Oksa A., et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the di.N.A.S. randomized trial. J Am Soc Nephrol 13 6 (2002) 1615-1625
27. Dedov I., Shestakova M., Vorontzov A., and Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 12 11 (1997) 2295-2300
28. Achour A., Kacem M., Dibej K., Skhiri H., Bouraoui S., and El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 18 5 (2005) 568-574
29. Heerspink H.L., Greene T., Lewis J.B., et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 23 6 (2008) 1946-1954
30. Wenzel R.R., Littke T., Kuranoff S., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20 3 (2009) 655-664
31. Tilton R.G., Chang K., Hasan K.S., et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42 2 (1993) 221-232
32. Suji G., and Sivakami S. DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 1067 (2006) 191-199
33. Forbes J.M., Soulis T., Thallas V., et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44 1 (2001) 108-114
34. Wilkinson-Berka J.L., Kelly D.J., Koerner S.M., et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51 11 (2002) 3283-3289
35. Kang Z., Li H., Li G., and Yin D. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products. Amino Acids 30 1 (2006) 55-61
36. Chetyrkin S.V., Mathis M.E., Ham A.J., Hachey D.L., Hudson B.G., and Voziyan P.A. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: Inhibition by pyridoxamine. Free Radic Biol Med 44 7 (2008) 1276-1285
37. Voziyan P.A., Metz T.O., Baynes J.W., and Hudson B.G. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277 5 (2002) 3397-3403
38. Chetyrkin S.V., Zhang W., Hudson B.G., Serianni A.S., and Voziyan P.A. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47 3 (2008) 997-1006
39. Onorato J.M., Jenkins A.J., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275 28 (2000) 21177-21184
40. Degenhardt T.P., Alderson N.L., Arrington D.D., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61 3 (2002) 939-950
41. Alderson N.L., Chachich M.E., Youssef N.N., et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63 6 (2003) 2123-2133
42. Alderson N.L., Chachich M.E., Frizzell N., et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47 8 (2004) 1385-1395
43. Zheng F., Zeng Y.J., Plati A.R., et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70 3 (2006) 507-514
44. Tanimoto M., Gohda T., Kaneko S., et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56 2 (2007) 160-167
45. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., and Thornalley P.J. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52 8 (2003) 2110-2120
46. Hammes H.P., Du X., Edelstein D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 3 (2003) 294-299
47. Nakamura S., Makita Z., Ishikawa S., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 5 (1997) 895-899
48. Figarola J.L., Scott S., Loera S., et al. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab Res Rev 21 6 (2005) 533-544
49. Izuhara Y., Nangaku M., Takizawa S., et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23 2 (2008) 497-509
50. Lassila M., Seah K.K., Allen T.J., et al. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15 8 (2004) 2125-2138
51. Peppa M., Brem H., Cai W., et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26 5 (2006) 430-436
52. Thallas-Bonke V., Lindschau C., Rizkalla B., et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53 11 (2004) 2921-2930
53. Coughlan M.T., Thallas-Bonke V., Pete J., et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. Endocrinology 148 2 (2007) 886-895
54. Zieman S.J., Melenovsky V., Clattenburg L., et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25 3 (2007) 577-583
55. Kass D.A., Shapiro E.P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 13 (2001) 1464-1470
56. Cheng G., Wang L.L., Long L., et al. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol 152 8 (2007) 1196-1206
57. Joshi D., Gupta R., Dubey A., et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 54 1 (2009) 72-81
58. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 12 (2001) 2792-2808
59. Schmidt A.M., Hori O., Cao R., et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 suppl 3 (1996) S77-S80
60. Wautier J.L., and Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27 5 pt 1 (2001) 535-542
61. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 pt 3 (2003) 1097-1109
62. Yamamoto Y., Doi T., Kato I., et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci 1043 (2005) 562-566
63. Jensen L.J., Denner L., Schrijvers B.F., Tilton R.G., Rasch R., and Flyvbjerg A. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol 188 3 (2006) 493-501
64. Navarro J.F., Mora C., Rivero A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33 3 (1999) 458-463
65. Dettelbach H.R., and Aviado D.M. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 25 1 (1985) 8-26
66. Navarro J.F., Mora C., Maca M., and Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42 1 (2003) 53-61
67. Lin S.L., Chen Y.M., Chien C.T., Chiang W.C., Tsai C.C., and Tsai T.J. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13 12 (2002) 2916-2929
68. Navarro J.F., Milena F.J., Mora C., Leon C., and Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26 6 (2006) 562-570
69. Harmankaya O., Seber S., and Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25 3 (2003) 465-470
70. Navarro J.F., Mora C., Muros M., and Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 16 7 (2005) 2119-2126
71. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., and Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 52 3 (2008) 454-463
72. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 6865 (2001) 813-820
73. Scivittaro V., Ganz M.B., and Weiss M.F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278 4 (2000) F676-F683
74. Kang N., Alexander G., Park J.K., et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 56 5 (1999) 1737-1750
75. Toyoda M., Suzuki D., Honma M., et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 66 3 (2004) 1107-1114
76. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 6 (1998) 859-866
77. Koya D., Haneda M., Nakagawa H., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14 3 (2000) 439-447
78. Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272 5262 (1996) 728-731
79. Kelly D.J., Zhang Y., Hepper C., et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52 2 (2003) 512-518
80. Gilbert R.E., Kim S.A., Tuttle K.R., et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 30 4 (2007) 995-996
81. Tuttle K.R., McGill J.B., Haney D.J., Lin T.E., Anderson P.W., PKC-DRS, PKC-DMES, and and PKC-DRS 2 Study Groups. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2 4 (2007) 631-636
82. Chabrashvili T., Tojo A., Onozato M.L., et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39 2 (2002) 269-274
83. Tojo A., Asaba K., and Onozato M.L. Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 11 8 (2007) 1011-1018
84. Riganti C., Costamagna C., Doublier S., et al. The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol 228 3 (2008) 277-285
85. Asaba K., Tojo A., Onozato M.L., et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67 5 (2005) 1890-1898
86. Nam S.M., Lee M.Y., Koh J.H., et al. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res Clin Pract 83 2 (2009) 176-182
87. Shi X.Y., Hou F.F., Niu H.X., et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149 4 (2008) 1829-1839
88. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 57 2 (2008) 460-469
89. Gambaro G., and van der Woude F.J. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 11 2 (2000) 359-368
90. Weiss R., Niecestro R., and Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67 18 (2007) 2681-2696
91. Maxhimer J.B., Somenek M., Rao G., et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54 7 (2005) 2172-2178
92. Gambaro G., Cavazzana A.O., Luzi P., et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42 2 (1992) 285-291
93. Solini A., Vergnani L., Ricci F., and Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 20 5 (1997) 819-823
94. Poplawska A., Szelachowska M., Topolska J., Wysocka-Solowie B., and Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 38 2 (1997) 109-114
95. Sulikowska B., Olejniczak H., Muszynska M., et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol 26 6 (2006) 621-628
96. Kohan D.E. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 15 1 (2006) 34-40
97. Sorokin A., and Kohan D.E. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285 4 (2003) F579-F589
98. Hargrove G.M., Dufresne J., Whiteside C., Muruve D.A., and Wong N.C. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58 4 (2000) 1534-1545
99. Bruno C.M., Meli S., Marcinno M., Ierna D., Sciacca C., and Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J Biol Regul Homeost Agents 16 2 (2002) 114-117
100. Benigni A., Colosio V., Brena C., Bruzzi I., Bertani T., and Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47 3 (1998) 450-456
101. Benigni A., Zoja C., Corna D., et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44 2 (1993) 440-444
102. Sasser J.M., Sullivan J.C., Hobbs J.L., et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18 1 (2007) 143-154
103. Petersen M., Thorikay M., Deckers M., et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 73 6 (2008) 705-715
104. Moon J.A., Kim H.T., Cho I.S., Sheen Y.Y., and Kim D.K. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 70 7 (2006) 1234-1243
105. Sugaru E., Nakagawa T., Ono-Kishino M., et al. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 290 4 (2006) F813-F820
106. Sugaru E., Nakagawa T., Ono-Kishino M., et al. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. Am J Nephrol 26 1 (2006) 50-58
107. Yang Y.L., Liu Y.S., Chuang L.Y., et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology 150 2 (2009) 727-740
108. Sugimoto H., Grahovac G., Zeisberg M., and Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56 7 (2007) 1825-1833
109. Nguyen T.Q., and Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?. Pharm Res 25 10 (2008) 2416-2426
110. Mitu G.M., Wang S., and Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 293 5 (2007) F1641-F1648
111. Wordinger R.J., Zode G., and Clark A.F. Focus on molecules: gremlin. Exp Eye Res 87 2 (2008) 78-79
112. Dolan V., Murphy M., Sadlier D., et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45 6 (2005) 1034-1039
113. Nguyen T.Q., Roestenberg P., van Nieuwenhoven F.A., et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 19 11 (2008) 2098-2107
114. Mason R.M. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?. J Cell Commun Signal 3 2 (2009) 95-104
115. Jaffa A.A., Usinger W.R., McHenry M.B., et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 93 5 (2008) 1893-1900
116. Turk T., Leeuwis J.W., Gray J., et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 57 7 (2009) 623-631
117. Yokoi H., Mukoyama M., Nagae T., et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15 6 (2004) 1430-1440
118. Guha M., Xu Z.G., Tung D., Lanting L., and Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21 12 (2007) 3355-3368
119. Liu E., Morimoto M., Kitajima S., et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 18 7 (2007) 2094-2104
120. Mendel D.B., Laird A.D., Smolich B.D., et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15 1 (2000) 29-41
121. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., and Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17 11 (2006) 3093-3104
122. Kelly D.J., Buck D., Cox A.J., Zhang Y., and Gilbert R.E. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 293 2 (2007) F565-F574
123. Advani A., Kelly D.J., Advani S.L., et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 104 36 (2007) 14448-14453